Affymax, Inc. (Nasdaq:AFFY) will host a teleconference and webcast on Monday, July 16, 2007, at 10:00 a.m. Eastern time to review its Hematide™ clinical development program. Hematide is the company’s lead drug in development for the treatment of anemia.
Interested parties can listen to the live call by dialing (800) 810-0924 from the U.S. or (913) 981-4900 internationally. There also will be a live and archived webcast that can be accessed by visiting www.affymax.com and going to the Investors section. A telephone replay will be available for seven days following the conclusion of the call by dialing (888) 203-1112 from the U.S. or (719) 457-0820 for international callers and entering passcode 2846279.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax’s lead product candidate, Hematide™, is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic kidney disease and cancer. For additional information, please visit www.affymax.com.